Circa Scientific has announced the launch of its innovative Crosswise radiofrequency (RF) transseptal access system, which is designed to provide precise puncture of the septal wall with a streamlined, zero-exchange workflow.
The Crosswise system delivers RF energy directly to the tip of a shapeable, radiopaque cannula, enabling precise navigation and controlled crossing during procedures requiring left heart access, such as atrial fibrillation (AF) ablations, left atrial appendage occlusions (LAAOs), and mitral valve interventions. That is according to a Circa press release.
The release also notes that the device’s zero-exchange design allows clinicians to maintain guidewire accessibility throughout, enhancing procedural efficiency by eliminating additional steps and reducing the need for extra consumables.
“The introduction of Crosswise represents a meaningful advancement in transseptal access,” said Lee Geist, president and chief executive officer (CEO) at Circa. “The system is designed to offer consistent performance while enhancing control, visibility, procedural efficiency and potential cost savings for physicians.”
Gregory Feld (Sulpizio Cardiovascular Center, University of California San Diego [UCSD], San Diego, USA), who participated in the early clinical experience with the system, commented: “Crosswise is a valuable addition to our EP [electrophysiology] lab, offering significant benefits for the many procedures requiring transseptal access. Its seamless integration with our existing tools and techniques ensures it adapts effortlessly to our established workflow.”
Crosswise is the first commercial release of a new product under Circa’s ‘CardioCentric’ strategy to expand its product portfolio with advanced solutions for complex medical interventions in cardiac EP and interventional cardiology.
